Weight Loss Pipeline • 2026-2027

The GLP-1 Pipeline: What's Coming Next

By MeetPeptide Research Team

Last updated: March 2026

Five next-generation weight loss drugs are racing toward approval — oral small molecules, dual GLP-1/amylin agonists, and dual GLP-1/glucagon compounds. Some could outperform Wegovy by 2027.

0
New Drugs
In Pipeline
0
% Weight Loss
Top Candidates
0
First Expected
Approval
Why This Matters

The GLP-1 Revolution Is Just Getting Started

Semaglutide (Wegovy) and tirzepatide (Zepbound) changed obesity treatment — but the next wave of drugs could be even more powerful, more convenient, or both.

📢 The Pipeline Is Evolving Rapidly

This guide covers the 5 most advanced GLP-1 pipeline drugs with published Phase 2+ data. Clinical trial timelines shift — check ClinicalTrials.gov for current status. Data shown is from published trials; individual results vary.

Orforglipron
Eli Lilly
💊 Oral
12.4% Weight Loss
72 Weeks
2026 FDA Submit

First true oral small-molecule GLP-1 agonist. Unlike peptide-based oral GLP-1s (Rybelsus), orforglipron doesn't require food timing restrictions — a potential game-changer for accessibility.

Mechanism: Once-daily oral small molecule GLP-1 receptor agonist. Direct GLP-1 binding with high selectivity.
Cagrisema
Novo Nordisk
💉 Injection
20.4% Weight Loss
68 Weeks
Late 2026 Expected

Combined GLP-1 + amylin agonist. Combines cagrilintide (long-acting amylin analog) with semaglutide. Targets both pathways for enhanced satiety and glucose control.

Mechanism: Dual agonist: GLP-1 receptor + amylin receptor. Enhanced satiety signaling through amylin pathway, slower gastric emptying.
Survodutide
Boehringer Ingelheim / Zealand Pharma
🔬 Phase 3
62% MASH Improve
Phase 2 Data
2026-27 Timeline

Dual GLP-1/glucagon agonist with Breakthrough Therapy designation for MASH. Direct liver fat clearance via glucagon — the strongest liver fat data of any GLP-1.

Mechanism: Dual GLP-1 + glucagon receptor agonist. Glucagon drives hepatic fat oxidation and thermogenesis. Breakthrough designation for MASH.
Pemvidutide
Altimmune
🔬 Phase 3
54.7% Liver Fat ↓
1:1 GLP-1:GcG
2026 Phase 3

Liver-focused dual GLP-1/glucagon with balanced 1:1 ratio. Also being studied for alcohol use disorder (RECLAIM trial). Strong liver fat reduction.

Mechanism: Balanced dual GLP-1 + glucagon (1:1 ratio). Targets liver fat directly. Also being investigated for AUD via GLP-1's effect on reward pathways.
Mazdutide (IBI362)
Innovent Biologics / Eli Lilly
✅ Approved (China)
20.1% Weight Loss
2025 Approved
✓ Beat Semaglutide

First dual GLP-1/glucagon agonist approved anywhere — now approved in China (2025). GLORY-2 trial showed 20.1% weight loss. DREAMS-3 beat semaglutide head-to-head in type 2 diabetes.

Mechanism: Dual GLP-1 + glucagon receptor agonist. First approved dual agonist globally. Demonstrated superiority to semaglutide in T2D (DREAMS-3).
Latest Data — 2025–2026

Trial Updates: The Numbers Keep Moving

Published data from 2025–2026 trials across all five pipeline drugs. This is where the real picture gets interesting.

Orforglipron — ATTAIN Program

The ATTAIN trial program produced multiple published readouts across obesity and T2D populations:

  • ▸ ATTAIN-1 (2025, NEJM): 12.4% weight loss at 72 weeks. 54.6% of participants lost ≥10%, 36% lost ≥15%.
  • ▸ ATTAIN-2 (2025): 10.5% loss in T2D population — harder to treat than obesity-only. A1C reduction of 1.8 percentage points.
  • ▸ ATTAIN-MAINTAIN (2026): Successfully maintained weight in patients switching from injectable GLP-1s to oral orforglipron — a significant practical finding.
  • ▸ ACHIEVE-2/5 (2025–2026): An additional 2.1% A1C reduction when orforglipron was added on top of existing insulin therapy.
CagriSema — REDEFINE Program

The REDEFINE trials showed cagrisema approaching bariatric surgery territory — and in one head-to-head, came close to tirzepatide:

  • ▸ REDEFINE 1 (2025): 20.4% weight loss at 68 weeks across 3,417 participants — one of the largest obesity drug trials ever.
  • ▸ REDEFINE 2 (2025): 15.7% loss in T2D — higher than semaglutide in comparable T2D populations.
  • ▸ REDEFINE 4 (2026): Head-to-head vs tirzepatide at 84 weeks — cagrisema 23.0% vs tirzepatide 25.5%. Not a win, but competitive within striking distance of the current market leader.
  • ▸ REDEFINE 11: Higher-dose cohort expected H1 2027. Could push numbers above 25%.
Survodutide — Phase 3 Trials

Phase 2 weight loss was 18.7% at 46 weeks (54.7% of participants lost ≥15%). Phase 3 is now enrolling for both obesity and liver disease:

  • ▸ SYNCHRONIZE-1: 726 participants enrolled. Primary obesity efficacy trial. Results expected 2026.
  • ▸ SYNCHRONIZE-2: 755 participants. T2D and weight management co-primary endpoints. Results expected 2026.
  • ▸ LIVERAGE: MASH (fatty liver) Phase 3 trial. Building on Phase 2's 62% MASH improvement — the best MASH data of any drug class.
  • ▸ LIVERAGE-Cirrhosis: Extends LIVERAGE to the more advanced liver disease population.
Pemvidutide — IMPACT & RECLAIM

The IMPACT Phase 2b trial published in The Lancet (2025) produced striking liver data — and an unexpected second indication emerged:

  • ▸ IMPACT (Lancet 2025): 48-week results. Liver fat reduced 54.7% with 1.8mg vs −8.2% placebo. ELF score (liver fibrosis marker) improved −0.58 vs +0.16 placebo. Liver stiffness −3.97 kPa vs −0.03 kPa placebo. Body weight −7.5% vs −0.2% placebo.
  • ▸ RECLAIM trial: Pemvidutide is being evaluated for alcohol use disorder (AUD). GLP-1 receptor activation appears to dampen reward pathway responses to alcohol — potentially extending this drug class into addiction medicine.
Mazdutide — GLORY & DREAMS Trials, Chinese Approvals
  • ▸ GLORY-2 (2025): 20.1% body weight loss at 60 weeks. 48.7% of participants achieved ≥20% weight loss — a bariatric-surgery-level threshold.
  • ▸ DREAMS-3 (2025): Head-to-head vs semaglutide in T2D. Mazdutide won: 48% of participants achieved both A1C <7% and ≥10% weight loss vs 21% on semaglutide.
  • ▸ Approved for obesity: China, June 2025 — first dual GLP-1/glucagon agonist approved anywhere in the world.
  • ▸ Approved for T2D: China, September 2025. Real-world data is now accumulating from the Chinese market — the first such data for any dual agonist globally.
Head-to-Head

Complete Pipeline Comparison

All 5 pipeline drugs compared against current leaders (semaglutide, tirzepatide, retatrutide).

Drug Company Mechanism Route Weight Loss Timeline Status
Orforglipron Eli Lilly GLP-1 Oral 12.4% (72w) FDA 2026 Phase 3
Cagrisema Novo Nordisk GLP-1 + Amylin Weekly Inj 20.4% (68w) Late 2026 NDA Filed
Survodutide Boehringer/Zealand GLP-1 + GcG Weekly Inj 62% MASH 2026-27 Phase 3
Pemvidutide Altimmune GLP-1 + GcG Weekly Inj 54.7% liver fat 2026 Phase 3
Mazdutide Innovent/Lilly GLP-1 + GcG Weekly Inj 20.1% Approved China 2025
Retatrutide Eli Lilly GLP-1 + GIP + GcG Weekly Inj 28% (48w) 2026 Phase 3
Tirzepatide Eli Lilly GLP-1 + GIP Weekly Inj 22.5% (72w) Approved FDA Approved
Semaglutide Novo Nordisk GLP-1 Weekly Inj 15% (68w) Approved FDA Approved
Timeline

When Will They Be Available?

Expected approval timeline for the top 5 GLP-1 pipeline drugs.

December 2025
Cagrisema NDA Submitted
Novo Nordisk submitted New Drug Application to FDA. If approved, could launch late 2026 — making it the first of the pipeline drugs to reach patients.
2025
Mazdutide Approved in China
Innovent's dual GLP-1/glucagon became the first dual agonist approved anywhere. Now launching in China under the Mazdutide brand name.
Mid-2026
Orforglipron FDA Submission
Eli Lilly's oral small-molecule GLP-1 on track for FDA submission mid-2026. Could be first convenient oral alternative to injectables.
Late 2026
Cagrisema Potential Approval
If FDA review goes smoothly, cagrisema could be available by late 2026 — combining semaglutide's mechanism with amylin for enhanced results.
2026-2027
Survodutide & Pemvidutide Phase 3
Both dual GLP-1/glucagon agonists in Phase 3 development. Survodutide has Breakthrough Therapy for MASH. Potential approvals 2027-2028.
2026
Retatrutide Approval Expected
Eli Lilly's triple agonist (GLP-1 + GIP + glucagon) showing 28% weight loss. FDA decision expected 2026.
What Makes Each Different

Mechanism & Target Population

How each pipeline drug targets different pathways and patient populations.

💊
Oral Convenience
Orforglipron is the only oral small molecule in late-stage trials. No injections, no food timing restrictions like Rybelsus. Could expand access significantly.
🫀
Liver-Focused
Survodutide and pemvidutide target liver fat directly via glucagon. Best for patients with MASH/NAFLD. Survodutide shows 62% MASH improvement — best ever.
🔄
Dual Amylin
Cagrisema adds amylin agonism to GLP-1. The amylin pathway adds satiety signaling and slows gastric emptying. Novo Nordisk's bet on differentiation.
🇨🇳
First Approval
Mazdutide is already approved in China — first dual GLP-1/glucagon anywhere. Real-world data emerging. DREAMS-3 showed beat semaglutide in T2D.
🍷
Addiction Potential
Pemvidutide being studied for alcohol use disorder (RECLAIM trial). GLP-1 agonists reduce reward pathway activation — potentially useful for addiction treatment.
🏆
Highest Efficacy
Retatrutide (triple agonist) leads with 28% weight loss. Cagrisema and mazdutide at ~20%. The multi-agonist approach appears to drive greater efficacy.
Who Might Benefit

Which Drug Is Right For You?

Target populations for each pipeline drug based on mechanism and trial data.

✅ Orforglipron: Best For
  • needle-averse patients who want GLP-1 benefits
  • Those who can't tolerate injections weekly
  • Patients wanting convenience (no food timing)
  • Those preferring oral medication options
  • Anyone with good adherence to daily pills
✅ Cagrisema: Best For
  • Maximum weight loss with established semaglutide backbone
  • Those who've responded well to semaglutide
  • Patients wanting proven dual mechanism
  • Novo Nordisk brand loyalists
  • Those with type 2 diabetes (improved HbA1c)
✅ Survodutide: Best For
  • Patients with MASH/NAFLD (fatty liver disease)
  • Those needing direct liver fat clearance
  • Breakthrough Therapy — priority review likely
  • Patients who need both weight loss + liver health
  • Those who've plateaued on current GLP-1s
✅ Pemvidutide: Best For
  • Liver-focused weight loss (54.7% liver fat reduction)
  • Patients interested in addiction research (AUD)
  • Balanced GLP-1/glucagon ratio preference
  • Those in clinical trials (Phase 3 starting 2026)
  • Combination of obesity + fatty liver
✅ Mazdutide: Best For
  • Access to first approved dual agonist (China)
  • Head-to-head semaglutide beater (DREAMS-3)
  • T2D patients (beat semaglutide on HbA1c)
  • Those wanting proven efficacy data
  • Access to global markets (eventual US/EU)
🔜 Wait for Retatrutide
  • Triple agonist showing 28% weight loss
  • Highest efficacy of any GLP-1 to date
  • FDA decision expected 2026
  • GLP-1 + GIP + glucagon all in one
  • May become new gold standard
Related Resources

Dive Deeper Into GLP-1 Research

💉
Semaglutide Research Results
Complete clinical trial data for Wegovy/Ozempic
→
💉
Tirzepatide Research Results
Mounjaro/Zepbound dual-agonist data
→
🏆
Retatrutide Results
Triple agonist showing 28% weight loss
→
⚖️
Retatrutide vs Semaglutide
Head-to-head comparison of GLP-1s
→
🔄
Ozempic Alternatives Guide
Every weight loss option compared
→
💪
GLP-1 Muscle Loss Prevention
Preserve lean mass on GLP-1s
→

🛒 Recommended Products

Support your weight loss journey with these research-backed tools.

⚖️ Smart Scale Track weight + body fat % 📏 Measuring Tape Track waist circumference 🍱 Meal Prep Containers Portion control support 💪 Whey Protein Preserve muscle mass 🏋️ Resistance Bands Home strength training 💉 Insulin Syringes 29G For peptide administration

Affiliate links help support MeetPeptide at no extra cost to you.

Bottom Line

Key Takeaways

✅ What We Know
  • 5 advanced GLP-1 pipeline drugs with Phase 2+ data
  • Orforglipron: first true oral small-molecule GLP-1 (FDA 2026)
  • Cagrisema: NDA submitted December 2025, potential late 2026 approval
  • Mazdutide: approved in China (2025), first dual agonist anywhere
  • Survodutide: 62% MASH improvement (best ever), Breakthrough designation
  • Pemvidutide: 54.7% liver fat reduction, also being studied for AUD
  • Retatrutide (triple agonist) leads with 28% weight loss
  • Dual/triple agonists appear more effective than GLP-1 alone
⚠️ What We Don't Know
  • Final FDA approval timelines (subject to change)
  • Pricing and insurance coverage for new drugs
  • Long-term safety data (most trials ongoing)
  • Comparative head-to-head trials between pipeline drugs
  • Real-world efficacy vs clinical trial conditions
  • Optimal sequencing between different mechanisms
  • Combination effects with other medications
⚠️ Important Disclaimer

This page is for educational and informational purposes only. The drugs discussed are research compounds and pipeline drugs not yet approved by the FDA (except mazdutide in China). All data cited comes from clinical trials and published research. Dosages, timelines, and approval statuses are subject to change. Always consult a qualified, licensed healthcare provider before starting any new medication. Nothing on this page constitutes medical advice. Clinical trial data shown from different studies — direct comparisons should be made with caution.